Five core IP legal principles in life sciences

Comprehensive and effective IP due diligence in life science transactions is essential. This is especially true of emerging and growth life science companies, where a single asset protected by strong IP can command hundreds of millions of dollars.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB year in review: A shifting landscape and outlook for 2026

2 January 2026 With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.

Americas

5 ways the USPTO director is changing US innovation

24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.

Americas

Mirum targets generics in quartet of suits over liver treatment

22 December 2025 Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.

More features

PTAB year in review: A shifting landscape and outlook for 2026

From Edwards to Insulet: Three key medical device cases of 2025

5 ways the USPTO director is changing US innovation

Mirum targets generics in quartet of suits over liver treatment

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

Regeneron v Alvotech: The big impact

SCOTUS shuts the door on Entresto ‘after-arising technology’ review

Morgan Lewis continues coast-to-coast US expansion with life sciences specialist

Five core IP legal principles in life sciences

More on this story

Editor's picks

Editor's picks

More features